Great Point Partners Decreased Biocryst Pharmaceuticals (Call) (BCRX) Stake, Zillow Group Class C Capital Stock (Z) Shorts Decreased By 9.54%

June 27, 2017 - By Richard Conner

Zillow Group Class C Capital Stock (NASDAQ:Z) had a decrease of 9.54% in short interest. Z’s SI was 19.07 million shares in June as released by FINRA. Its down 9.54% from 21.09 million shares previously. With 1.84M avg volume, 10 days are for Zillow Group Class C Capital Stock (NASDAQ:Z)’s short sellers to cover Z’s short positions. The SI to Zillow Group Class C Capital Stock’s float is 16.68%. About 2.00 million shares traded or 29.87% up from the average. Zillow Group, Inc. (NASDAQ:Z) has risen 50.16% since June 27, 2016 and is uptrending. It has outperformed by 33.46% the S&P500.

Great Point Partners Llc decreased Biocryst Pharmaceuticals (Call) (BCRX) stake by 31.03% reported in 2016Q4 SEC filing. Great Point Partners Llc sold 225,000 shares as Biocryst Pharmaceuticals (Call) (BCRX)’s stock declined 16.46%. The Great Point Partners Llc holds 500,000 shares with $3.17M value, down from 725,000 last quarter. Biocryst Pharmaceuticals (Call) now has $464.99M valuation. The stock decreased 4.28% or $0.26 during the last trading session, reaching $5.82. About 796,063 shares traded. BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) has risen 75.08% since June 27, 2016 and is uptrending. It has outperformed by 58.38% the S&P500.

Investors sentiment increased to 1.38 in Q4 2016. Its up 0.38, from 1 in 2016Q3. It increased, as 14 investors sold BCRX shares while 23 reduced holdings. 19 funds opened positions while 32 raised stakes. 52.04 million shares or 2.90% more from 50.57 million shares in 2016Q3 were reported. Royal Bank & Trust Of Canada holds 0% of its portfolio in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) for 4,128 shares. Legal General Group Pcl accumulated 0% or 17,727 shares. The New York-based Ny State Common Retirement Fund has invested 0% in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX). Principal Finance Grp Inc owns 13,205 shares. Fmr Ltd Llc reported 737,723 shares stake. Sei Invests owns 442 shares or 0% of their US portfolio. Vhcp Mgmt Limited Co accumulated 1.16M shares or 7.86% of the stock. Susquehanna Intll Grp Inc Llp holds 370,416 shares. Morgan Stanley owns 327,965 shares or 0% of their US portfolio. Invesco holds 966,854 shares. State Board Of Administration Of Florida Retirement Sys invested 0% in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX). Tower Ltd Liability Co (Trc) holds 0% or 7,239 shares. Blackrock Ltd Llc reported 38,500 shares or 0% of all its holdings. Blackrock has invested 0% in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX). 45,913 are owned by Nationwide Fund Advsrs.

Among 11 analysts covering BioCryst Pharmaceuticals (NASDAQ:BCRX), 8 have Buy rating, 0 Sell and 3 Hold. Therefore 73% are positive. BioCryst Pharmaceuticals had 22 analyst reports since August 7, 2015 according to SRatingsIntel. FBR Capital maintained BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) on Tuesday, February 9 with “Outperform” rating. Bank of America downgraded BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) on Wednesday, November 11 to “Underperform” rating. JMP Securities upgraded the stock to “Market Outperform” rating in Friday, December 16 report. The firm has “Buy” rating by Jefferies given on Wednesday, January 6. The stock of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) earned “Overweight” rating by Piperjaffray on Friday, August 12. The stock of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) earned “Neutral” rating by JP Morgan on Tuesday, February 9. On Friday, August 7 the stock rating was upgraded by Zacks to “Sell”. The stock of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) has “Neutral” rating given on Friday, October 9 by Bank of America. JMP Securities downgraded the shares of BCRX in report on Thursday, August 4 to “Market Perform” rating. The rating was maintained by Jefferies on Friday, August 5 with “Hold”.

Great Point Partners Llc increased Neurocrine Biosciences Inc (NASDAQ:NBIX) stake by 355,920 shares to 750,000 valued at $29.03M in 2016Q4. It also upped Merrimack Pharmaceuticals Inc (NASDAQ:MACK) stake by 2.56M shares and now owns 5.00M shares. Avexis Inc was raised too.